'Buy' Eris Lifesciences Shares Maintains PL Capital Post Q1 Results; Revises Target Price
Eris maintains revenue growth guidance of 15-20% for FY26E, adds PL Capital
(Photo: Company website)
Eris has multiple growth levers such as broad-based offerings in the derma segment, tapping GLP-1 market, demand supply mismatch in insulin segment, creating large injectable franchise across India and RoW market and benefits of operating leverage.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
PL Capital Report
Eris Lifesciences Ltd.’s Q1 FY26 Ebitda was broadly in line with our estimate (Rs 2.75 billion; up 11% YoY). Though Q1 FY26 revenue growth (up 7.4% YoY) was muted, we see pick up in coming quarters as insulin shortages stabilize, export pick up and likely additional market share gain from human insulin market.
Eris has opted for inorganic route to diversify and scale up existing portfolio. This has been implemented without diluting margins. We expect margins to scale up from the current level of 35% in FY25 as revenue scales up from recent acquisitions, which are currently operating at sub-optimal profitability.
The company has multiple growth levers such as broad-based offerings in the derma segment, tapping GLP-1 market, demand supply mismatch in insulin segment, creating large injectable franchise across India and RoW market and benefits of operating leverage.
Our FY26 and FY27E Ebitda broadly remains unchanged. We maintain ‘Buy’ rating with revised target price of Rs 1,975 (valuing at 20x EV/Ebitda on FY27E vs 18 times earlier).
Click on the attachment to read the full report:
ALSO READ
Kansai Nerolac Q1 Review: PL Capital Retains 'Add' On Favorable Risk-Reward — Check Target Price
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
